Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ledipasvir (GS-5885) 是一种丙型肝炎病毒 NS5A 抑制剂。它也是 P-糖蛋白抑制剂和乳腺癌抗性蛋白抑制剂。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 453 | 现货 | ||
2 mg | ¥ 663 | 现货 | ||
5 mg | ¥ 997 | 现货 | ||
10 mg | ¥ 1,660 | 现货 | ||
25 mg | ¥ 2,830 | 现货 | ||
50 mg | ¥ 4,190 | 现货 | ||
100 mg | ¥ 5,880 | 现货 | ||
500 mg | ¥ 12,300 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,610 | 现货 |
产品描述 | Ledipasvir (GS-5885) is a Hepatitis C Virus NS5A Inhibitor. The mechanism of action of ledipasvir is as a P-Glycoprotein Inhibitor, and Breast Cancer Resistance Protein Inhibitor. |
靶点活性 | NS5A (1b replicon):4 pM(EC50), NS5A (1a replicon):34 pM(EC50) |
体外活性 | Ledipasvir has GT1a and 1b EC50 values of 31 and 4 pM, respectively, and protein-adjusted EC50 values of 210 pM (GT1a) and 27 pM (GT1b) and the intrinsic EC50 of 39 is 310 fM for GT1a and 40 fM for GT1b. Ledipasvir is highly protein-bound both in human serum and in the cell-culture medium (containing 10% BSA) of the replicon assay[1]. Ledipasvir exhibits an EC50 value of 141 nM against the JFH/3a-NS5A replicon[2]. |
体内活性 | Ledipasvir is remarkable not only on the basis of its high replicon potency but also on the basis of its low clearance, good bioavailability, and long half-lives in rat, dog, and monkey as well as low predicted clearance in human. The pharmacokinetics of Ledipasvir is measured in rats and dogs. Ledipasvir exhibits good half-lives (rat 1.83 ± 0.22 hr, dog 2.63 ± 0.18 hr) in plasma, low systemic clearance (CL), and moderate volumes of distribution (Vss) that are greater than total body water volume[1]. |
别名 | GS-5885, 雷迪帕韦 |
分子量 | 889 |
分子式 | C49H54F2N8O6 |
CAS No. | 1256388-51-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: < 1 mg/mL (insoluble or slightly soluble)
DMSO: 93 mg/mL (104.6 mM)
Ethanol: 93 mg/mL (104.6 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO / Ethanol | 1 mM | 1.1249 mL | 5.6243 mL | 11.2486 mL | 28.1215 mL |
5 mM | 0.225 mL | 1.1249 mL | 2.2497 mL | 5.6243 mL | |
10 mM | 0.1125 mL | 0.5624 mL | 1.1249 mL | 2.8121 mL | |
20 mM | 0.0562 mL | 0.2812 mL | 0.5624 mL | 1.4061 mL | |
50 mM | 0.0225 mL | 0.1125 mL | 0.225 mL | 0.5624 mL | |
100 mM | 0.0112 mL | 0.0562 mL | 0.1125 mL | 0.2812 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Ledipasvir 1256388-51-8 Microbiology/Virology Proteases/Proteasome HCV Protease SARS-CoV inhibit HCV Inhibitor SARS coronavirus GS-5885 GS 5885 雷迪帕韦 GS5885 Hepatitis C virus inhibitor